Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Childhood apraxia of speech CAS is a challenging motor speech disorder that limits childrens ability to communicate effectively, often continuing into later life. Researchers are evaluating a new motor-based treatment called Dynamic Temporal and Tactile Cueing-Connect DTTC-Connect aimed at improving connected speech, where children with CAS usually face ongoing difficulties. This Phase II randomized controlled trial tests DTTC-Connects effectiveness in enhancing phrase accuracy, speech intelligibility, and speech motor control in children aged 3 years and 6 months to nearly 13 years. Participants receive DTTC-Connect treatment twice a week for eight weeks, with 45-minute sessions each time, totaling 16 sessions. The treatment uses a structured approach that gradually increases phrase complexity, starting from two-word phrases and progressing through levels of support to encourage independent speech production. The study includes two groups an Immediate Treatment Group beginning right after diagnostic evaluation, and a Delayed Treatment Group starting treatment after an 8-week wait to account for natural development. Throughout the study, children undergo assessments before, during, and after treatment, including detailed speech evaluations, acoustic and movement analyses of lip and jaw, and caregiver reports on communicative participation. The main outcome is phrase accuracy, measured at several points up to 16 weeks post-treatment. Secondary outcomes include speech intelligibility, speech motor variability, and communicative participation. These measures help researchers understand the lasting effects of DTTC-Connect and how prior treatment influences progress.
Actively Recruiting
Researchers are investigating the use of an Artificial Intelligence-based tool to help match patients with advanced solid and blood cancers to appropriate clinical trials. This international registry study includes both adult and pediatric patients who have already been considered for clinical trial enrollment by their primary healthcare providers. The study aims to assess the feasibility, clinical usefulness, financial impact, and patient outcomes related to this AI-driven matching approach. The intervention involves a specialized software application that connects with existing electronic health records to extract and analyze individual patient data. This data is compared with a database of available clinical trials using machine learning algorithms to dynamically identify the best matches based on trial availability and patient characteristics. The study is observational and non-interventional, with treatment decisions made by the patients healthcare team supported by virtual tumor boards and AI reports. Data collection occurs every three months over about 36 months, including 24 months of patient enrollment and 12 months of follow-up. Participants will voluntarily enroll and continue receiving care as usual. Researchers will collect and analyze clinical data, biomarker information, and enrollment barriers to evaluate how many eligible patients actually enroll in trials and the impact on survival outcomes. The primary outcome is the proportion of patients eligible for versus actually enrolling in clinical trials, with secondary outcomes including overall survival, progression-free survival, and virtual tumor board use. The study plans to enroll over 50,000 patients worldwide to gather real-world evidence on this AI-assisted trial matching process.